ArticleFrontiers in molecular medicine2022

Three year results of Blessed: Expanded access for DeltaRex-G for an intermediate size population with advanced pancreatic cancer and sarcoma (NCT04091295) and individual patient use of DeltaRex-G for solid malignancies (IND# 19130).

Sant P Chawla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.